RECENTLY ACTIVATED ALLIANCE TRIALS
Alliance A072301 - Phase III trial of radiotherapy followed by adjuvant temozolomide in combination with the IDH inhibitor vorasidenib vs. placebo in IDH-mutated newly-diagnosed grade 3 astrocytomas
Overview: This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.
Study Chair: Ugonma Chukwueke, MD | Dana-Farber Cancer Institute
Activated: 03/06/2026 | To learn more about the trial, visit ClinicalTrials.gov.
ClinicalTrials.gov Identifier: NCT07215910.
Alliance A042302 - Phase III evaluation of fixed duration zanubrutinib plus sonrotoclax-based therapy compared to continuous zanubrutinib in previously untreated older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Overview: This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.
Study Chair: Jennifer Brown, MD, PhD | Dana-Farber Cancer Institute
Activated: Activated 03/06/2026 | To learn more about the trial, visit ClinicalTrials.gov.
ClinicalTrials.gov Identifier: NCT07321652.
Alliance A212101 - Evaluation of provider vs. patient mediated cascade genetic testing of first-degree relatives of patients with newly diagnosed colorectal cancer
Overview: This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.
Study Chair: Frank Sinicrope, MD | Mayo Clinic
Activated: 03/05/2026 | To learn more about the trial, visit ClinicalTrials.gov.
ClinicalTrials.gov Identifier: NCT07143487.
Alliance A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
Overview: This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients with hormone resistant prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Hormone resistant prostate cancer often has many cells containing a protein called prostate-specific membrane antigen (PSMA) on their surface. The normal cells in the prostate do not normally express as much PSMA protein on their surface as cancer cells. Lutetium 177 Lu PSMA RLT binds to the PSMA protein on the tumor cells. It builds up in these cells and gives off radiation that may kill them. Typically, this medication is given at the same dose every 6 weeks for up to 6 doses. In this trial, researchers want to see if treatment following the first two doses of lutetium 177 Lu PSMA RLT can be delayed until there is evidence of disease activity. This may be an effective way to improve quality of life without decreasing lifespan in patients with advanced prostate cancer.
Study Chair: Thomas Hope, MD | University of California San Francisco
Activated: 12/23/2025 | To learn more about the trial, visit ClinicalTrials.gov or read the news release.
ClinicalTrials.gov Identifier: NCT07200830.
A232402CD: PAGODA: Randomized trial of a proactive graduated dose modification algorithm for folfox chemotherapy to prevent unplanned delays
Overview: This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Study Chair: Gabriel Brooks, MD | Dartmouth Hitchcock Medical Center
Activated: 01/06/2026 | To learn more about the trial, visit ClinicalTrials.gov.
ClinicalTrials.gov Identifier: NCT07283939.
